Title:Platelet-Rich and Platelet-Poor Plasma Might Play Supportive Roles in Cancer Cell Culture: A Replacement for Fetal Bovine Serum?
Volume: 21
Issue: 16
Author(s): Mehdi Talebi, Mousa Vatanmakanian, Ali Mirzaei, Yaghoub Barfar, Maryam Hemmatzadeh, Milad A. Nahayati, Kobra Velaei, Asghar Hosseinzadeh, Behruz Yazdanpanah, Yahya Yahyavi, Ako Azimi, Mina Rahmani and Milad Z. Heydarabad*
Affiliation:
- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj,Iran
Keywords:
Platelet-rich plasma, platelet-poor plasma, YKL-40, CCRF-CEM, cancer cell, FBS.
Abstract:
Background: Platelet-Rich (PRP) and Platelet-Poor plasma (PPP) are widely used in research and
clinical platforms mainly due to their capacities to enhance cell growth. Although the short half-life (5 days)
and the high price of platelet products pose challenges regarding their usage, they maintain the growth regulatory
functions for weeks. Thus, we aimed to assess the supplementary values of these products in human CCRF-
CEM cancer cells. Mechanistically, we also checked if the PRP/PPP treatment enhances YKL-40 expression
as a known protein regulating cell growth.
Methods: The PRP/PPP was prepared from healthy donors using manual stepwise centrifugation and phase separation.
The viability of the cells treated with gradient PRP/PPP concentrations (2, 5, 10, and 15%) was measured
by the MTT assay. The YKL-40 mRNA and protein levels were assessed using qRT-PCR and western
blotting. The data were compared to FBS-treated cells.
Results: Our findings revealed that the cells treated by PRP/PPP not only were morphologically comparable to
those treated by FBS but also showed greater viability at the concentrations of 10 and 15%. Moreover, it was
shown that PRP/PPP induce cell culture support, at least in part, via inducing YKL-40 expression at both mRNA
and protein levels in a time- and dose-dependent manner.
Conclusion: Collectively, by showing cell culture support comparable to FBS, the PRP/PPP might be used as
good candidates to supplement the cancer cell culture and overcome concerns regarding the use of FBS as a
non-human source in human cancer research.
